Whittier Trust’s Sarepta Therapeutics SRPT Stock Holding History

Whittier Trust’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-674	Closed	-$43K	–	1548
2025 Q1	$43K	Hold	674	–	–	﹤0.01%	961
2024 Q4	$82K	Buy	674 +27	+4%	+$3.31K	﹤0.01%	837
2024 Q3	$80.8K	Hold	647	–	–	﹤0.01%	838
2024 Q2	$102K	Hold	647	–	–	﹤0.01%	766
2024 Q1	$83.8K	Hold	647	–	–	﹤0.01%	821
2023 Q4	$62.4K	Sell	647 -4	-0.6%	-$384	﹤0.01%	871
2023 Q3	$78.9K	Buy	651 +4	+0.6%	+$452	﹤0.01%	824
2023 Q2	$74.1K	Hold	647	–	–	﹤0.01%	845
2023 Q1	$89.2K	Hold	647	–	–	﹤0.01%	842
2022 Q4	$83.8K	Hold	647	–	–	﹤0.01%	858
2022 Q3	$72K	Sell	647 -14	-2%	-$1.41K	﹤0.01%	894
2022 Q2	$50K	Hold	661	–	–	﹤0.01%	954
2022 Q1	$52K	Buy	661 +14	+2%	+$1.07K	﹤0.01%	967
2021 Q4	$58K	Buy	+647	New	+$55.3K	﹤0.01%	946

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Whittier Trust's SRPT Position: Q2 2025 in Review

Whittier Trust sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 674 shares — an estimated $43K sold.

Whittier Trust first reported a position in SRPT in Q4 2021 and held it in 14 quarters. The position peaked at $102K in Q2 2024. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

Whittier Trust reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
Whittier Trust sold 674 Sarepta Therapeutics shares in Q2 2025, an estimated $43K.
Whittier Trust first reported a position in Sarepta Therapeutics in Q4 2021 and held it in 14 quarters.
Whittier Trust's Sarepta Therapeutics position peaked at $102K in Q2 2024.
362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Whittier Trust's 13F filing for Q2 2025, filed 30 Jul 2025.